A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Clinical trial NCT06986785 · RECRUITING

Trial details

NCT number: NCT06986785
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Hepatocellular Carcinoma

Start date: 2025-06-24
Primary completion: 2027-05-01
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.